文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

产肠毒素大肠杆菌疫苗:推动产品开发、许可与全球可及性的优先活动

Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access.
PubMed 文献 · Vaccine · 2021-05-06

产肠毒素大肠杆菌(ETEC)所致腹泻在低中收入国家儿童中造成显著发病和死亡,且可能影响儿童生长与发育。疫苗可能是最经济公平的一级预防手段,但需更多数据加速投资与决策。本文综述ETEC疫苗研发管线,并制定疫苗开发策略以指导优先活动。

要点

  • ETEC腹泻在低中收入国家儿童中疾病负担重,可致长期生长和认知发育受损。
  • 疫苗可能是最经济公平的一级预防手段,但需更多数据支持投资与决策。
  • 需进一步阐明ETEC感染与发育迟缓的关联及不适当抗生素治疗对耐药性的影响。

核心结论

  • ETEC疫苗可能具有显著公共卫生影响且具成本效益,但需更多数据加速投资和决策。

研究设计与样本

  • 本文为综述,回顾了ETEC疫苗研发管线并制定了ETEC疫苗开发策略。

主要发现

  • ETEC腹泻在低中收入国家儿童中造成显著发病和死亡,且长期后果日益受到关注。
  • 提供安全饮用水和卫生设施及适当临床护理对减少ETEC负担至关重要,但覆盖不均衡。
  • 不适当或不足的抗生素治疗可能导致抗菌药物耐药(AMR),需进一步阐明。

临床怎么用

  • 疫苗开发策略为研究者、资助者和制造商提供优先活动框架,以缩短疫苗许可和使用时间。

局限性

  • 需更多数据理解ETEC感染与体格和认知发育迟缓及教育延迟的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diarrhoeal disease attributable to enterotoxigenic Escherichia coli (ETEC) causes substantial morbidity and mortality predominantly in paediatric populations in low- and middle-income countries. In addition to acute illness, there is an increasing appreciation of the long-term consequences of enteric infections, including ETEC, on childhood growth and development. Provision of potable water and sanitation and appropriate clinical care for acute illness are critical to reduce the ETEC burden. However, these interventions are not always practical and may not achieve equitable and sustainable coverage. Vaccination may be the most cost-effective and equitable means of primary prevention; however, additional data are needed to accelerate the investment and guide the decision-making process for ETEC vaccines. First, to understand and quantify the ETEC disease burden, additional data are needed on the association between ETEC infection and physical and cognitive stunting as well as delayed educational attainment. Furthermore, the role of inappropriate or inadequate antibiotic treatment of ETEC-attributable diarrhoea may contribute to the development of antimicrobial resistance (AMR) and needs further elucidation. An ETEC vaccine that mitigates acute diarrhoeal illness and minimizes the longer-term disease manifestations could have significant public health impact and be a cost-effective countermeasure. Herein we review the ETEC vaccine pipeline, led by candidates compatible with the general parameters of the Preferred Product Characteristics (PPC) recently developed by the World Health Organization. Additionally, we have developed an ETEC Vaccine Development Strategy to provide a framework to underpin priority activities for researchers, funders and vaccine manufacturers, with the goal of addressing globally unmet data needs in the areas of research, product development, and policy, as well as commercialization and delivery. The strategy also aims to guide prioritization and co-ordination of the priority activities needed to minimize the timeline to licensure and use of ETEC vaccines, especially in in low- and middle-income countries, where they are most urgently needed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Khalil I, Walker R, Porter CK, et al. Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access. Vaccine. 2021. PMID: 33965254. doi:10.1016/j.vaccine.2021.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。